Practical considerations and role of Daratumumab retreatment for relapsed refractory Multiple Myeloma

Abstract

Daratumumab is a first-in-class anti-CD38 monoclonal antibody approved for multiple myeloma. Because of the incidence and severity of infusion-related reactions with initial doses, daratumumab is administered over 6.5 hours for the first dose. With the need for pre-medication and monitoring, patients are scheduled for a 10-hour infusion visit. In an attempt to improve patient experience as well as optimize clinic space, additional pre-medications have been added with the initial doses and rapid infusion rate has been introduced for subsequent doses.